The DOI matches its Crossref record; 218 of the 218 references it cites were found in a registry or an index.
Current Clinical Applications of Ω‐6 and Ω‐3 Fatty Acids
Abstract
BACKGROUND: Recent years have brought a resurgence of research interest in fatty acids, with studied fields running the gamut of human disease. This movement has run in parallel with an increased interest in using nutrition modalities as therapeutic measures, as opposed to their conventional role as energy sources. The aim of this manuscript is to provide a basic review of current clinical applications of omega-6 and omega-3 fatty acids, with a particular focus on the latter. METHODS: A selective review of the voluminous literature, including randomized controlled trials, meta-analyses, population studies, and case reports, was used to compile data and identify trends in pertinent clinical applications of fatty acid therapy. CONCLUSIONS: There are a myriad of disorders and maladies that seem to benefit from fatty acid supplementation, specifically omega-3 fatty acids. It has clearly been shown that omega-3 fatty acid supplementation provides a protective benefit in heart disease, and in particular sudden cardiac death. Rheumatoid arthritis (RA) is another disease entity that has been proven to benefit from this nutrition intervention, with improvement in symptoms and diminished nonsteroidal antiinflammatory drug (NSAID) usage. In addition, many psychiatric disorders, particularly schizophrenia and major depressive disorder (MDD), have shown positive results when supplementation has been used as an adjunct to standard pharmacotherapy. The remainder of clinical applications for omega-3 fatty acids requires further investigation. Specifically, according to preliminary clinical evidence, parenteral administration of fatty acids warrants further study.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The differences identified could be due to structural characteristics of the two fatty acids as well as their ability to produce different metabolite species [137,138].”
From Potential Roles of n-3 PUFAs during Skeletal Muscle Growth and Regeneration (2018) · cites this paper as [138]
Citations
Cites
Items 201–218 of 218
Schizophrenia, tardive dyskinesia and essential fatty acids
Vaddadi, K. S., Gilleard, C. J., Soosai, E., Polonowita, A., Gibson, R. A., & Burrows, G. D. (1996) · Schizophrenia Research · doi:10.1016/0920-9964(95)00095-x · Cited by 39
Keicher, U., Koletzko, B. V., & Reinhardt, D. (1995) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1995.tb01967.x · Cited by 38
Omega-3 Fatty Acid for Schizophrenia
Horrobin, D. F. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.188 · Cited by 37
Davies, C. L., Loizidou, M., Cooper, A. J., & Taylor, I. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00181-1 · Cited by 36
Surette, M. E., Koumenis, I. L., Edens, M. B., Tramposch, K. M., Clayton, B., Bowton, D. L., & Chilton, F. H. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80117-0 · Cited by 35
Hardman, W. E., Sun, L., Short, N. J., & Cameron, I. L. (2005) · Cancer Cell International · doi:10.1186/1475-2867-5-12 · Cited by 35
Seasonal Allergic Rhinoconjunctivitis and Fatty Acid Intake
Wakai, K., Okamoto, K., Tamakoshi, A., Lin, Y., Nakayama, T., & Ohno, Y. (2001) · Annals of Epidemiology · doi:10.1016/s1047-2797(00)00182-4 · Cited by 30
Dyskinesias and their treatment with essential fatty acids: a review
Vaddadi, K. S. (1996) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/s0952-3278(96)90151-9 · Cited by 29
The Influence of Immunomodulatory Diets on Transplant Success and Complications
Alexander, J. W., Metze, T., McIntosh, M. J., Goodman, H. R., First, M. R., MUNDA, R. T., Cardi, M. A., Austin, J. N., Goel, S., Safdar, S., et al. (2005) · Transplantation · doi:10.1097/01.tp.0000148802.04879.27 · Cited by 28
Is there a case for n-3 fatty acid supplementation in cystic fibrosis?
Cawood, A. L., Carroll, M. P., Wootton, S. A., & Calder, P. C. (2005) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/00075197-200503000-00008 · Cited by 26
Kenny, F. S., Gee, J. M. W., Nicholson, R. I., Ellis, I. O., Morris, T. M., Watson, S. A., Bryce, R. P., & Robertson, J. F. R. (2001) · International Journal of Cancer · doi:10.1002/ijc.1213 · Cited by 24
Bougnoux, P., Chajès, V., Germain, E., Hubert, B., Lhuillery, C., Floch, O. L., Body, G., & Calais, G. (1999) · Lipids · doi:10.1007/bf02562251 · Cited by 24
Sex Differences in n-3 and n-6 Fatty Acid Metabolism in EFA-Depleted Rats
Huang, Y.-S., & Horrobin, D. F. (1987) · Experimental Biology and Medicine · doi:10.3181/00379727-185-42547 · Cited by 24
What Is So Special about the Diet of Greece? The Scientific Evidence
Simopoulos, A. P. (2005) · KARGER eBooks · doi:10.1159/000088275 · Cited by 22
Walker, N. P., Fox, H. C., & Whalley, L. J. (1999) · The British Journal of Psychiatry · doi:10.1192/bjp.174.2.101 · Cited by 22
Cendrowski, W. (1986) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.1986.tb08003.x · Cited by 15
Whitehouse, P. A., Cooper, A. J., Johnson, C. D., & Adrian, T. E. (2003) · Pancreatology · doi:10.1159/000073651 · Cited by 10
n-3 fatty acid-enriched eggs, lipids, and Western diet: time for change.
Simopoulos, A. P. (1994) · PubMed · Cited by 7
Research works printed but not linked: 6
- American Heart Association, 1992, Heart and Stroke Facts
- Begin ME, 1986, Differential killing ofhuman carcinoma cells supplemented with n‐3 and n‐6 polyunsaturated fattyacids, J Natl Cancer Inst., 77, 1053
- American Cancer Society, 2004, Breast cancer facts and figures2003– 2004
- Simmer K, 2001, Long‐chain polyunsaturated fatty acid supplementation ininfants born at term, Cochrane Database Syst Rev., CD000376
- Simmer K, 2004, Long‐chain polyunsaturated fatty acidsupplementation in preterm infants, Cochrane Database Syst Rev., CD000375
- Weber PC, 1989, Are We What We Eat? Fatty Acids in Nutritionand in Cell Membranes: Cell Functions and Disorders Induced by Dietary Conditions: Report No. 4, 9
Cited by
Sorted by citations
Russo, G. L. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.10.020 · Cited by 843
The plasma lipidomic signature of nonalcoholic steatohepatitis
Puri, P., Wiest, M. M., Cheung, O., Mirshahi, F., Sargeant, C., Min, H., Contos, M. J., Sterling, R. K., Fuchs, M., Zhou, H., et al. (2009) · Hepatology · doi:10.1002/hep.23229 · Cited by 655
Goulet, O., Antébi, H., Wolf, C., Talbotec, C., Alcindor, L., Corriol, O., Lamor, M., & Colomb, V. (2010) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607110363614 · Cited by 234
Abundance of active ingredients in sea-buckthorn oil
Zielińska, A., & Nowak, I. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0469-7 · Cited by 194
Supplementation with Omega-3 Fatty Acids in Psychiatric Disorders: A Review of Literature Data
Bozzatello, P., Brignolo, E., Grandi, E. D., & Bellino, S. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5080067 · Cited by 193
Metadata
- Authors
- Lee, S., Gura, K. M., Kim, S., Arsenault, D. A., Bistrian, B. R., & Puder, M.
- Affiliations
- Boston Children's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Puder, Mark
- Venue
- Nutrition in Clinical Practice
- Publisher
- Wiley
- Published
- 2006-08
- Volume
- 21
- Issue
- 4
- Pages
- 323-341
- ISSN
- 0884-5336 (ISSN-L)
- 1941-2452
- OpenAlex
- W2345098798
- Cited by
- 100
- References
- 218
- Citations by year
- 2026: 1 · 2024: 3 · 2022: 2 · 2021: 10 · 2020: 2 · 2019: 5 · 2018: 2 · 2017: 5 · 2016: 4 · 2015: 4 · 2014: 5 · 2013: 1 · 2012: 4
- FWCI
- 1.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nutrition in Clinical Practice (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Physical Sciences › Chemistry › Organic Chemistry › Edible Oils Quality and Analysis
- Life Sciences › Agricultural and Biological Sciences › Aquatic Science › Aquaculture Nutrition and Growth
- Keywords
- omega-3 fatty acids, omega-6 fatty acids, fatty acid supplementation, dietary therapy, cardiovascular disease, sudden cardiac death, rheumatoid arthritis, NSAID use, schizophrenia, major depressive disorder, mental illness
- MeSH terms
- Animals, Arthritis, Rheumatoid, Mental Disorders, Disease Models, Animal, Heart Diseases, Humans, Fatty Acids, Omega-3, Randomized Controlled Trials as Topic, Treatment Outcome, Dietary Supplements, Fatty Acids, Omega-6
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
